Evidence map›Paper›PMID 34327369›Full record

ReviewThe Lancet regional health. Western Pacific2021

Maintaining cancer services during the COVID-19 pandemic: the Aotearoa New Zealand experience.

Elinor Millar, Jason Gurney, Suzanne Beuker, Moahuia Goza, Mary-Ann Hamilton, Claire Hardie, Christopher Gca Jackson, Michelle Mako, Tom Middlemiss, Myra Ruka and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Elinor MillarTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Jason GurneyTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Suzanne BeukerTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Moahuia GozaHei Āhuru Mōwai Māori Cancer Leadership, Victoria St, Hamilton, New Zealand.
Mary-Ann HamiltonWaikato District Health Board, Pembroke Street, Hamilton, New Zealand.
Claire HardieMidcentral District Health Board, Ruahine Street, Palmerston North, New Zealand.
Christopher Gca JacksonDepartment of Medicine, University of Otago, Great King St, Dunedin, New Zealand.
Michelle MakoTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Tom MiddlemissHutt Valley District Health Board, Boulcott St, Lower Hutt, New Zealand.
Myra RukaHei Āhuru Mōwai Māori Cancer Leadership, Victoria St, Hamilton, New Zealand.
Nicole WillisTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Diana SarfatiTe Aho o Te Kahu, Cancer Control Agency, Molesworth St, Wellington, New Zealand.
Health Promotion Agency · NZUniversity of Otago · NZWaikato District Health Board · NZHutt Hospital · NZPalmerston North Hospital · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 caused significant disruption to cancer services around the world. The health system in Aotearoa New Zealand has fared better than many other regions, with the country being successful, so far, in avoiding sustained community transmission. However, there was a significant initial disruption to services across the cancer continuum, resulting in a decrease in the number of new diagnoses of cancer in March and April 2020. Te Aho o Te Kahu, Aotearoa New Zealand's national Cancer Control Agency, coordinated a nationwide response to minimise the impact of COVID-19 on people with cancer. The response, outlined in this paper, included rapid clinical governance, a strong equity focus, development of national clinical guidance, utilising new ways of delivering care, identifying and addressing systems issues and close monitoring and reporting of the impact on cancer services. Diagnostic procedures and new cancer registrations increased in the months following the national lockdown, and the cumulative number of cancer registrations in 2020 surpassed the number of registrations in 2019 by the end of September. Cancer treatment services - surgery, medical oncology, radiation oncology and haematology - continued during the national COVID-19 lockdown in March and April 2020 and continued to be delivered at pre-COVID-19 volumes in the months since. We are cautiously optimistic that, in general, the COVID-19 pandemic does not appear to have increased inequities in cancer diagnosis and treatment for Māori in Aotearoa New Zealand.

Indexed as

cancercancer policycancer servicescoronavirusCOVIDCOVID-19

Identifiers

PMID34327369
PMCPMC8315642
OpenAlexW3172613000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.